---
schema_version: '1.0'
id: news-20260731-de8271
url: https://bciintel.com/news/synchron-2026-pivotal-trial-stentrode-fda-approval/
url_hash: de82719163128d602af3eff0a574560704583a600a445bf7361f56a3a71ad386
canonical_url: https://bciintel.com/news/synchron-2026-pivotal-trial-stentrode-fda-approval
source: bciintel.com
category: news/health
category_raw: sci_medical
region: null
tags: []
lang: null
published_at: null
fetched_at: '2026-07-31T00:39:18.772411Z'
updated_at: '2026-07-31T00:39:56Z'
status: published
content_hash: null
content_changed_at: null
license_note: link-only
summary: null
summary_source: null
summary_en: null
entities:
- name: BCI
  type: method
- name: Intel
  type: organization
key_facts: []
related: []
related_auto:
- name: ニューラルリンク
  type: artifact
  weight: 1.0
- name: 進化至上主義
  type: concept
  weight: 1.0
- name: fNIRS
  type: method
  weight: 1.0
- name: BrainChip
  type: organization
  weight: 1.0
- name: ニューロモルフィックチップ
  type: artifact
  weight: 1.0
title: Synchron Eyes 2026 Pivotal Trial | BCI Intel
---

# Synchron Eyes 2026 Pivotal Trial | BCI Intel

## TL;DR
（要約なし・原文はリンク先を参照 / No summary available; see the source link.）

## Key Points
- (なし)

## Details
(本文なし。リンク先参照)

## Source
元記事: [Synchron Eyes 2026 Pivotal Trial | BCI Intel](https://bciintel.com/news/synchron-2026-pivotal-trial-stentrode-fda-approval/)